Replimune’s Lead Drug Hits Second FDA Wall, Triggering Survival Mode

The U.S. Food and Drug Administration has delivered a potentially fatal blow to Replimune Group Inc., issuing a second complete rejection for its lead skin cancer therapy RP1 within a year. The decision, announced on April 10, 2026, has vaporized nearly two-thirds of the company’s market value and forced an immediate corporate overhaul to conserve cash.

In a devastating repeat of July 2025, the regulator’s new review team unanimously concluded that data from the IGNYTE clinical trial was insufficient to prove the drug’s substantial contribution. The FDA specifically cited concerns that the company had ignored its feedback on trial design dating back to 2021, a charge Replimune disputes. The agency’s core issue is the difficulty of isolating RP1’s effect when it is combined with the already-approved immunotherapy nivolumab, casting doubt on the entire study approach.

Investors reacted with a swift and severe sell-off. The stock price collapsed by 58% in after-hours trading, plummeting from $4.76 to $1.75 by the end of the week. This crash reflected the high stakes; a positive approval scenario had been heavily priced into the equity.

Wall Street analysts moved just as quickly, shredding their former bullish targets. Barclays slashed its price target to $3.00 from $17.00, downgrading the stock to Equalweight. BMO Capital Markets was even more pessimistic, cutting its rating to Underperform and reducing its target to a mere $2.00 from $27.00. Both Piper Sandler and Cantor Fitzgerald downgraded their ratings to Neutral, with Piper Sandler setting a new target of $4.00.

Should investors sell immediately? Or is it worth buying Replimune?

Facing a future without near-term revenue from RP1, Replimune’s management announced drastic cost-cutting measures the very next day. The plan includes significant layoffs and a sharp reduction in U.S. manufacturing capacity. The company’s financial runway is now critically short. With cash reserves of approximately $270 million and an annual cash burn rate of around $283 million, funding is projected to last only until the end of the first quarter of 2027.

The crisis extends beyond the immediate rejection. The FDA has now questioned the design of the ongoing Phase 3 trial, IGNYTE-3, and has requested a meeting to discuss whether protocol adjustments will suffice or if an entirely new study is required. An interim analysis for overall survival data is not expected until 2027, leaving RP1 inaccessible to patients outside of clinical trials for the foreseeable future.

Replimune continues to publicly challenge the FDA’s decision, pointing to trial data showing a 34% response rate and a median progression-free survival of 30.6 months compared to 4.4 months on prior therapy. However, the company’s strategic focus is now forcibly shifting to its remaining pipeline, notably the successor candidate RP2, which is in a Phase 2/3 study for metastatic uveal melanoma. For investors, Replimune has transformed overnight into a smaller, cash-strapped company betting on its next-in-line assets after the failure of its primary catalyst.